Day One Biopharmaceuticals, Inc. (DAWN) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

19/25

Growth 5 Margin 5 Expansion 4 Platform 2 Financial 3

latest quarter score

Earnings Reports

19
Day One Biopharmaceuticals (DAWN) Q4 2025: Ojemda Revenue Jumps 172% as Persistence and Pipeline Reshape Growth Trajectory
February 25, 2026
15
Day One Biopharmaceuticals (DAWN) Q3 2025: Ojemda Prescriptions Jump 18%, Deepening Second-Line Standardization
November 05, 2025
17
Day One Biopharmaceuticals (DAWN) Q2 2025: Ojemda Scripts Jump 15% as Persistence Drives $140M+ Guidance
August 06, 2025
Day One (DAWN) Q1 2025: Ojemda Scripts Jump 16% as Depth Strategy Accelerates
July 06, 2025

Browse all companies